SCHEDULE: Morgan Stanley Adjusts Terns Pharmaceuticals Stake

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of Terns Pharmaceuticals, Inc. common stock.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amendment to their Schedule 13G for Terns Pharmaceuticals, Inc.
• As of March 31, 2026, Morgan Stanley beneficially owns 6,422,021 shares, representing 5.6% of the class of securities, with shared voting and dispositive power.
• Morgan Stanley Capital Services LLC, a wholly-owned subsidiary, has ceased to be the beneficial owner of more than five percent of the class of securities, holding 5,764,462 shares, representing 4.9%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports changes in beneficial ownership by an institutional investor and does not contain operational or financial performance data for Terns Pharmaceuticals, Inc.

Negatives

• Morgan Stanley Capital Services LLC has fallen below the 5% beneficial ownership threshold, indicating a reduction in their stake or a reclassification of holdings.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to beneficial ownership reporting.

Management Comments

• Morgan Stanley Capital Services LLC has ceased to be the beneficial owner of more than five percent of the class of securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant shareholders, indicating changes in holdings rather than operational performance. The reduction in stake by Morgan Stanley Capital Services LLC may reflect portfolio adjustments or strategic shifts.

Stakeholder Impact

• Shareholders may note the change in institutional ownership, which could influence market perception or trading dynamics, although the filing itself does not indicate a change in control or strategic direction for Terns Pharmaceuticals.

Key Dates

Keywords

Schedule 13G, Terns Pharmaceuticals, Morgan Stanley, Beneficial Ownership, Securities Filing, Amendment, Common Stock